NFKB1 and diabetic kidney disease: In addition, recent experimental studies indicate that suppression of NF-κB activation by various agents, such as 1,25-dihydroxyvitamin D3 [103], cilostazol [104], and curcumin [105], could lead to amelioration of DKD, suggesting the importance of NF-κB as a therapeutic target of DKD.